Published in Cancer Genet Cytogenet on October 01, 1984
Chromosomal instability confers intrinsic multidrug resistance. Cancer Res (2011) 3.70
EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet (1999) 1.70
Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol (2003) 1.23
MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer (1998) 1.21
Molecular genetic analysis of flow-sorted ovarian tumour cells: improved detection of loss of heterozygosity. Br J Cancer (1994) 1.14
Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity. Am J Pathol (2012) 1.14
Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. Br J Cancer (2001) 1.04
Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era. Nat Rev Clin Oncol (2015) 0.87
Contribution of Aurora-A and -B expression to DNA aneuploidy in gastric cancers. Surg Today (2013) 0.85
Prognostic relevance of DNA content in childhood renal tumours. Br J Cancer (1989) 0.84
Oncocytic tumours of the salivary gland, kidney, and thyroid: nuclear DNA patterns studied by flow cytometry. Br J Cancer (1986) 0.84
Heterogeneity of DNA content in multiple synchronous hepatocellular carcinomas. Br J Cancer (1997) 0.84
Hodgkin's disease: a flow cytometric study. J Clin Pathol (1988) 0.83
Tumour proliferation, angiogenesis, and ploidy status in human colon cancer. J Clin Pathol (2005) 0.82
Quantitative pathology: historical background, clinical research and application of nuclear morphometry and DNA image cytometry. Libyan J Med (2006) 0.82
DNA aberrations in the epithelial cell component of adamantinoma of long bones. Am J Pathol (1995) 0.81
Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features. Am J Pathol (1992) 0.81
The development of a cell array and its combination with laser-scanning cytometry allows a high-throughput analysis of nuclear DNA content. Am J Pathol (2000) 0.81
Molecular genetic evidence for unifocal origin of advanced epithelial ovarian cancer and for minor clonal divergence. Br J Cancer (1995) 0.80
Ploidy and S-phase fraction are correlated with lymphovascular space invasion that is predictive of outcomes in endometrial cancer. Int J Clin Oncol (2011) 0.79
Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erbB-2 protein and HCG in operable muscle-invasive bladder cancer. Br J Cancer (1993) 0.79
Origins of ... flow cytometry and applications in oncology. J Clin Pathol (1997) 0.78
The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma. Leukemia (2015) 0.78
DNA ploidy in primary testicular cancer. Br J Cancer (1991) 0.78
Carcinoma of the anal canal and flow cytometric DNA analysis. Br J Cancer (1989) 0.76
Flow cytometric DNA measurement and cytomorphometric analysis of formalin fixed rat mammary tumours. Br J Cancer (1991) 0.76
Multivariate analyses of DNA index, p62c-myc, and clinicopathological status of patients with ovarian cancer. J Clin Pathol (1998) 0.75
Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120). Blood Cancer J (2016) 0.75
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Hybridization of synthetic oligodeoxyribonucleotides to phi chi 174 DNA: the effect of single base pair mismatch. Nucleic Acids Res (1979) 14.12
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
A neural network classifier capable of recognizing the patterns of all major subcellular structures in fluorescence microscope images of HeLa cells. Bioinformatics (2001) 5.84
Automated recognition of patterns characteristic of subcellular structures in fluorescence microscopy images. Cytometry (1998) 5.27
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet (2001) 4.79
Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst (1995) 3.96
A method for incorporating macromolecules into adherent cells. J Cell Biol (1984) 3.77
TOPAS: an innovative proton Monte Carlo platform for research and clinical applications. Med Phys (2012) 3.57
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med (2001) 3.47
Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med (1993) 3.37
Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 3.22
DNA content and DNA-based centromeric index of the 24 human chromosomes. Science (1973) 3.08
Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med (1984) 3.06
The LNCaP cell line--a new model for studies on human prostatic carcinoma. Prog Clin Biol Res (1980) 2.97
Effect of bafilomycin A1 and nocodazole on endocytic transport in HeLa cells: implications for viral uncoating and infection. J Virol (1998) 2.93
Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst (1992) 2.82
Gardner syndrome in a man with an interstitial deletion of 5q. Am J Med Genet (1986) 2.78
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Endosome pH measured in single cells by dual fluorescence flow cytometry: rapid acidification of insulin to pH 6. J Cell Biol (1984) 2.76
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med (1988) 2.68
Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol (1992) 2.63
Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood (1998) 2.60
Proposed new data file standard for flow cytometry, version FCS 3.0. Cytometry (1997) 2.39
Chromosome measurement and sorting by flow systems. Proc Natl Acad Sci U S A (1975) 2.37
Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet (1995) 2.26
The journal "impact factor": a misnamed, misleading, misused measure. Cancer Genet Cytogenet (1998) 2.23
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood (1994) 2.11
Paraneoplastic hypokalemia in acute myeloid leukemia: a case of renin activity in AML blast cells. Ann Hematol (1996) 2.05
Regulation of endocytic pH by the Na+,K+-ATPase in living cells. Proc Natl Acad Sci U S A (1989) 2.03
Primary dexamethasone treatment of multiple myeloma. Blood (1992) 2.02
Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer (1999) 1.99
Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia (2008) 1.97
Culture of human leukemia cells. Cancer (1966) 1.94
Assay of vacuolar pH in yeast and identification of acidification-defective mutants. Proc Natl Acad Sci U S A (1989) 1.93
Automated identification of subpopulations in flow cytometric list mode data using cluster analysis. Cytometry (1985) 1.93
Disappearance of a structural chromatin protein A24 in mitosis: implications for molecular basis of chromatin condensation. Proc Natl Acad Sci U S A (1979) 1.91
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia (2000) 1.91
VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol (1990) 1.87
Structure of transcriptionally active chromatin. Proc Natl Acad Sci U S A (1975) 1.86
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant (2006) 1.85
Cellular DNA content as a marker of human multiple myeloma. Blood (1980) 1.83
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood (2001) 1.80
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia (2004) 1.77
Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry (1993) 1.77
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol (1993) 1.76
Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma (2005) 1.75
Apparent endocytosis of fluorescein isothiocyanate-conjugated dextran by Saccharomyces cerevisiae reflects uptake of low molecular weight impurities, not dextran. J Cell Biol (1987) 1.73
Combination chemotherapy with CHOP for recurrent thrombotic thrombocytopenic purpura. Br J Haematol (1997) 1.71
Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood (1998) 1.68
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol (1998) 1.68
Characterization of a new primary human pancreatic tumor line. Cancer Invest (1986) 1.67
Kinetics and temperature dependence of exposure of endocytosed material to proteolytic enzymes and low pH: evidence for a maturation model for the formation of lysosomes. J Cell Physiol (1987) 1.63
Cellular DNA content as a marker of neoplasia in man. Am J Med (1980) 1.62
Proteomic identification of the MYST domain histone acetyltransferase TIP60 (HTATIP) as a co-activator of the myeloid transcription factor C/EBPalpha. Leukemia (2008) 1.62
Graft-versus-myeloma effect: proof of principle. Blood (1996) 1.58
Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood (1998) 1.58
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood (1999) 1.57
Anaplastic myeloma with massive extramedullary involvement. Report of two cases. Cancer (1983) 1.54
Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer (2001) 1.53
Expression of interleukin-6 in Castleman's disease. Hum Pathol (1993) 1.53
Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood (1994) 1.52
A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones (2001) 1.52
Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). II. Biomarker studies. Cancer (1985) 1.51
[Ethics in medicine: needs and forms]. Internist (Berl) (1999) 1.51
Antibodies to intermediate filament proteins in the immunohistochemical identification of human tumours: an overview. Histochem J (1983) 1.50
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1994) 1.49
A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study. Clin Cancer Res (2001) 1.49
Application of long-term collagenase disaggregation for the cytogenetic analysis of human solid tumors. Cancer Genet Cytogenet (1986) 1.49
Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). I. Clinical description of resource. Cancer (1985) 1.48
Characterization of chromatin distribution in cell nuclei. Cytometry (1986) 1.48
Isopeptidase: a novel eukaryotic enzyme that cleaves isopeptide bonds. Proc Natl Acad Sci U S A (1982) 1.47
Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol (1996) 1.46
High-resolution kinetics of transferrin acidification in BALB/c 3T3 cells: exposure to pH 6 followed by temperature-sensitive alkalinization during recycling. Proc Natl Acad Sci U S A (1987) 1.45
Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood (1995) 1.45
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level. Br J Haematol (1997) 1.43
Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol (2001) 1.42
Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 1.41
[Paraneoplastic syndromes]. Internist (Berl) (1994) 1.40
[New possibilities in the technic of intravital microscopy of the skin]. Z Wiss Mikrosk (1970) 1.40
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood (2000) 1.39
Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Hum Pathol (1993) 1.39
Trisomy 14: a new entity within acute nonlymphocytic leukemia. Cancer Genet Cytogenet (1989) 1.39
Involvement of 6p in benign lipomas. A new cytogenetic entity? Cancer Genet Cytogenet (1989) 1.39